A leading RNAi therapeutics business.

Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics business, announced today that it’ll present fresh data from its ALN-TTR system at the VIIIth International Symposium on Familial Amyloidotic Polyneuropathy being held in Kumamoto, From November 20-22 Japan, 2011 treatments . This includes data from its blinded, randomized, placebo-controlled, single dose escalation Phase I clinical trial of ALN-TTR01 in sufferers with transthyretin -mediated amyloidosis . Related StoriesExpanded use for IntelliCap with further CE Mark for aspiration of fluidsLiposomal sizing and the Coulter theory: an interview with Professor Melvin E. KlegermanPresentations from Alnylam scientists at the conference include: a display titled ‘Quantitation of wild-type, V30M, and V122I serum TTR protein by an LC-MS/MS technique in human beings with amyloidogenic mutant TTR variants,on Sunday ‘ in the Oral presentation 2 session being held, 20 from 12:00 p November.m.

Certainly, ALN-TTR02 is our lead program in this effort and we expect to initiate a Phase II trial later on this year, accompanied by a pivotal trial starting in 2013,’ said Akshay K. Vaishnaw, M.D., Ph.D., Senior Vice Chief and President Medical Officer of Alnylam. ‘ALN-TTR02 utilizes our proprietary second-generation LNP technology that has shown significant potency improvements in both pre-clinical and medical studies. We quite definitely anticipate our anticipated reporting of TTR knockdown data from the Phase I study in the 3rd quarter of this 12 months.’ Related StoriesResearchers identify tumor suppressor genes that travel subset of melanomasPerisylvian polymicrogyria gene foundUnderstanding how schizophrenia affects workings of the brain’RNAi therapeutics represent a novel and fascinating approach for the treatment of ATTR, as this brand-new drug modality has the potential to produce a meaningful effect in the treatment of this devastating disease.